What to Expect With CAYSTON® (aztreonam for inhalation solution) | CAYSTON®

• Severe allergic reactions. Stop your treatment with CAYSTON and call your doctor right away if you have any symptoms of an allergic reaction, including:
  • Rash or swelling of your face
  • Throat tightness

  If you have a history of allergy to antibiotics such as penicillins, cephalosporins, and/or carbapenems, you may also be allergic to CAYSTON. It is important to tell your healthcare provider about any medication allergies you may have.

• Trouble breathing right after treatment with CAYSTON (bronchospasm). To decrease the chance of this happening, be sure to use your inhaled bronchodilator medicine before each treatment with CAYSTON. Stop treatment if chest tightness develops during nebulizer use.
• Decreases in FEV₁ after 28-day course of treatment. Improvements that you experience in your lung function during your 28-day course of treatment may not be continued when you stop treatment.

The most common side effects of CAYSTON include cough, nasal congestion, wheezing, sore throat, fever (may be more common in children than in adults), chest discomfort, stomach area (abdominal) pain, vomiting.

Tell your doctor if you have any new or worsening symptoms while taking CAYSTON and about any side effects that bother you or do not go away.

These are not all the possible side effects of CAYSTON. For more information, ask your doctor or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is CAYSTON?

CAYSTON is a prescription inhaled antibiotic used to improve breathing symptoms in people with cystic fibrosis (CF) who have a lung infection due to Pseudomonas aeruginosa (Pa). CAYSTON is not a treatment for infections caused by other bacteria or viruses, such as the common cold. CAYSTON is used only with the Altera^® Nebulizer System. It is not known if CAYSTON is safe and effective in children under the age of 7 or in patients with FEV₁ <25% or >75% predicted.

Please click here to see full Prescribing Information and here to read the complete FDA-approved Patient Information including the Patient Instructions for Use.